Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2019) [Effective from January 1, 2019]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2017: 100.00
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2017: 100.00
NAAS RATING 2018: 5.38

Int.J.Curr.Microbiol.App.Sci.2016.5(5): 971-974
DOI: http://dx.doi.org/10.20546/ijcmas.2016.505.102


Role of rapid detection of Clostridium difficile toxin gene versus its expression in symptomatic patients with suspected CDI in a tertiary care hospital in India
Hena Rani1*, Raman Sardana1, Leena Mendiratta1, Sohan L. Broor2,Sudha Kansal3 and Reetika Dawar1
1Departments of Microbiology, Indraprastha Apollo Hospitals, New Delhi, India
2Gastroenterology, Indraprastha Apollo Hospitals, New Delhi, India
3Critical Care Medicine, Indraprastha Apollo Hospitals, New Delhi, India
*Corresponding author
Abstract:

This study was planned to evaluate the performance of GeneXpert assay for the detection of Clostridium difficile toxin gene in stool specimens of patients suspected of having Clostridium difficile Infection (CDI), to compare its results with VIDAS based Enzyme Immunoassay (EIA) for the detection of Clostridium difficile toxin, to clinically correlate the positive results and to discuss the clinical utility of each of these two assays. Out of a total of 60 stool specimens processed by both GeneXpert and EIA, C. difficile toxin was detected in 03 (5%) patients by EIA and 05 (8.3%) patients by GeneXpert assay. All the five patients detected positive with either of these two assays showed good clinical correlation with respect to the previous antibiotic therapy and/or histopathological findings. So, both these assays in combination can be used as rapid diagnostic tools for making the definitive diagnosis of CDI. A positive GeneXpert assay is useful in acute conditions with strong suspicion of CDI and a negative VIDAS result should be followed by a more sensitive assay like GeneXpert in view of strong clinical suspicion.


Keywords: CDI,Xpert C. difficile assay,Enzyme immunoassay for C. difficile toxin.
Download this article as Download

How to cite this article:

Hena Rani, Raman Sardana, Leena Mendiratta, Sohan L. Broor, Sudha Kansal and Reetika Dawar. 2016. Role of rapid detection of Clostridium difficile toxin gene versus its expression in symptomatic patients with suspected CDI in a tertiary care hospital in India.Int.J.Curr.Microbiol.App.Sci. 5(5): 971-974. doi: http://dx.doi.org/10.20546/ijcmas.2016.505.102